Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Non-Current Assets (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Other Non-Current Assets for 3 consecutive years, with $79647.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 7.66% to $79647.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $79647.0, a 7.66% increase, with the full-year FY2025 number at $77945.0, changed N/A from a year prior.
  • Other Non-Current Assets was $79647.0 for Q4 2025 at Neuphoria Therapeutics, up from $78564.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $85235.9 in Q2 2022 to a low of $73982.0 in Q4 2024.
  • A 3-year average of $78942.4 and a median of $78564.0 in 2025 define the central range for Other Non-Current Assets.
  • Biggest YoY gain for Other Non-Current Assets was 7.66% in 2025; the steepest drop was 4.76% in 2025.
  • Neuphoria Therapeutics' Other Non-Current Assets stood at $85235.9 in 2022, then fell by 13.2% to $73982.0 in 2024, then rose by 7.66% to $79647.0 in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Other Non-Current Assets are $79647.0 (Q4 2025), $78564.0 (Q3 2025), and $77945.0 (Q2 2025).